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ABSTRACT
Introduction: Benepali was the first
etanercept (Enbrel) biosimilar to be approved
in the European Union. Both Benepali and
Enbrel are available as autoinjector devices. In
a recent survey, nurses from France, Germany,
Italy, Spain, and the United Kingdom (UK)
reported that their patients with rheumatoid
arthritis (RA) would prefer the Benepali
autoinjector compared to the Enbrel MYCLIC
autoinjector. To determine whether patients’
perceptions were similar to those of the nurses,
this survey evaluated patients’ perceptions and
preferences of the Benepali autoinjector versus
the Enbrel MYCLIC autoinjector in the same
five European countries.
Methods: Patients with RA using the Enbrel
MYCLIC autoinjector participated in a 25-min,
face-to-face questionnaire-interview. Patients
were also shown an instructional video and
device-handling leaflet, received a live
demonstration on the Benepali autoinjector,
and had access to both Benepali and Enbrel
MYCLIC training autoinjectors. Patients rated
the importance of ten autoinjector attributes on
a seven-point scale (1 = not important at all;
7 = extremely important) and provided their
autoinjector preferences based on specific
attributes. Patients also gave their opinion on
which autoinjector they would prefer to use for
self-injection.
Results: Overall, 220 patients participated in
the survey (France, n = 30; Germany, n = 65;
Italy, n = 67; Spain, n = 12; UK, n = 46). ‘Easy to
operate the self-injection’ was ranked as the
most important attribute (mean score of 6.8),
followed by ‘easy to grip’ (6.5), and
‘intuitive/self-explaining usage’ (6.3). Patients
preferred the Benepali autoinjector, with the
attribute of ‘easier to operate’ being a strong
differentiator compared to the Enbrel MYCLIC
autoinjector. Most patients (74%) reported that
they would prefer to use the Benepali
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autoinjector over the Enbrel MYCLIC
autoinjector. ‘Easy to operate the
self-injection’ and ‘button-free autoinjector’
were key drivers when selecting an autoinjector.
Conclusions: Patients in Europe reported a
preference for the Benepali autoinjector
compared to the Enbrel MYCLIC autoinjector.
This finding is consistent with results from a
recently reported nurse survey.
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antirheumatic drugs (csDMARDs), such as
methotrexate, hydroxychloroquine, and
sulfasalazine, have long been the mainstay of
treatment for RA, and their initiation in the
early stages of disease can curb or halt the
progressive synovitis and joint destruction,
thereby limiting disability [1–3]. However, an
improved understanding of the pathogenesis of
RA over the past decade has led to the
development of several biological DMARDs
(bDMARDs) that directly target components of
the RA inflammatory cascade, and have
transformed the management of this disease
[3]. The first targeted bDMARD for RA was the
tumor necrosis factor (TNF)-antagonist,
etanercept (Enbrel), which was approved by
the US Food and Drug Administration in 1998
[4]. Since then, a number of other bDMARDs
have been approved and are now commercially
available; many of these treatments are
administered by subcutaneous (SC) injection,
with a number of presentations and devices
currently being available (prefilled syringes, vial
and syringe, and autoinjector devices). A
number of studies have reported that patients
with RA prefer autoinjector devices over
conventional methods of treatment
administration, with patients citing such
factors as these devices being easier to use,
more convenient, more acceptable, less painful,
and less time-consuming [5–7].
Although bDMARDs are effective in reducing
RA symptoms, slowing disease progression, and
improving physical function and quality of life
[3, 8–10], they are costly [11]. Consequently, in
many countries, not all patients who may be
eligible for treatment with biological drugs
according to guidelines are prescribed these
drugs, with preference generally being given to
those with more severe and aggressive disease
[12]. Indeed, results from a cross-sectional study
estimated that, in total, 320 million people in
the European region (approximately 40%) have
severely restricted access to bDMARDs in cases
of RA, with barriers to access primarily being
financial and administrative [11]. However, the
patent expiry of some of these bDMARDs has
enabled the introduction of therapeutically
similar, and more affordable, alternatives—
known as biosimilars [13].
Benepali (manufactured by Biogen, Inc,
Cambridge, MA, USA) was the first etanercept
biosimilar to be approved in the European
Union (EU) in 2016. Benepali, which
underwent robust preclinical and clinical
(phase I and phase III) testing in both healthy
volunteers and patients with RA [14, 15], is
approved for all the adult indications for
which Enbrel is approved—namely,
moderate-to-severe RA, psoriatic arthritis, axial
spondyloarthritis (ankylosing spondylitis and
non-radiographic axial spondyloarthritis), and
plaque psoriasis [16]. Both Benepali and Enbrel
are available as autoinjector devices. In a recent
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European survey conducted in France,
Germany, Italy, Spain, and the United
Kingdom (UK), the majority of nurses (86%)
reported that their patients would prefer the
Benepali autoinjector compared to the Enbrel
MYCLIC autoinjector [17]. To determine
whether patients were in agreement with
nurses, this survey evaluated patients’
perceptions and preferences of the Benepali
autoinjector versus the Enbrel MYCLIC
autoinjector in the same five European
countries.
METHODS
This survey, which consisted of a 25-min,
face-to-face, structured, questionnaire-interview,
was designed to assess patient perceptions and
preferences for the Benepali autoinjector
compared to the Enbrel MYCLIC autoinjector.
The survey was conducted between December
2015 and April 2016 in France, Germany, Italy,
Spain, and the UK. The survey, including the
pilot survey, was conducted by Kantar Health,
an independent global market research and
consulting firm, based in Munich, Germany.
Kantar Health performed the survey in
accordance with market research guidelines,
data protection laws, and data privacy
legislation, ensuring the implementation of an
effective quality assurance system. Kantar
Health operates in compliance with ISO
20252:2012, the International Standard for
Market, Opinion and Social Research and, as a
member of numerous market research
associations, including Arbeitskreis Deutscher
Markt und Sozialforschungsinstitute e.V.
(ADM), the European Pharmaceutical
Marketing Research Association (EphMRA), the
Council for American Survey Research
Organizations (CASRO), and the European
Society for Opinion and Market Research
(ESOMAR), strictly adheres to the latest
industry codes of conduct and guidelines in
market research.
Patient Population
Patient recruitment was outsourced by Kantar
Health to another agency, Schmiedl
Marktforschung GmbH, who enrolled patients
from a number of sources, including patient
panels and patient-support groups, as well as
recommendations from nurses and physicians.
To be eligible to participate in the survey,
patients had to have been diagnosed with
moderate or severe RA by a physician and had
to be using the Enbrel MYCLIC autoinjector for
at least 1 month at the time of recruitment into
the survey. There were no specific exclusion
criteria for this survey. Patients provided
written consent before participating in the
survey and were compensated for their time
with an honorarium.
Questionnaire Design
The survey was developed in a two-stage
process, with the guidance on the interview
questions and process taken from a recent
survey in patients with relapsing–remitting
multiple sclerosis, which investigated patients’
perceptions of the importance of different
general attributes of autoinjectors [18].
Initially, an English structured quantitative
master questionnaire was created, which was
then tested and validated in pilot interviews
(n = 4) to ensure appropriate content, flow, and
clarity of the survey. During these pilot
interviews, respondents were asked to provide
those autoinjector attributes that they
considered to be the most important for
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inclusion in the main quantitative survey.
These interviews were also used to determine
whether respondents fully understood the
instructions provided with the questionnaire.
The final version of the English questionnaire
was then translated into four languages
(German, Italian, French, and Spanish). All
interviews were conducted in the relevant
local language and were performed by
experienced interviewers working on behalf of
the recruitment agency (Schmiedl
Marktforschung GmbH). Interviewer training
was conducted by Kantar Health via video
conference prior to commencement of the
survey, with scheduled weekly feedback calls
to check on the progress of the interviews and
to ensure that they were being performed
correctly.
During a 25-min face-to-face interview, each
patient was asked a series of questions in
sequence by the interviewer and all responses
were documented. In addition, patients were
shown an instructional video and
device-handling leaflet for the Benepali
autoinjector, received a live demonstration on
the Benepali training autoinjector, and were
given access to both the Benepali and Enbrel
MYCLIC training autoinjectors.
The questionnaire was broadly divided into
four sections. In the first section (Q1), patients
were asked to rate the importance of ten
attributes, when using an autoinjector device
in general for self-injection of their RA
treatment, on a seven-point scale (1 = not
important at all; 7 = extremely important).
The following attributes were assessed: (1) size
of the autoinjector, (2) attractive design of the
autoinjector, (3) easy to grip the autoinjector,
(4) easy to operate the self-injection with the
autoinjector, (5) audible feedback after
treatment has been successfully injected, (6)
visual feedback after treatment has been
successfully injected, (7) concealing the
injection needle in the injector body, (8)
intuitive/self-explaining usage, (9) button-free
autoinjector, and (10) weight of the
autoinjector. In the second section of the
questionnaire (Q2–Q11), patients were asked
for their preference of autoinjector (Benepali,
Enbrel MYCLIC, or both the same) based on
nine of the ten attributes assessed in section 1
(button-free device was excluded from this
section as this attribute related only to the
Benepali autoinjector). In the third section of
the questionnaire (Q12–Q13), patients were
asked which autoinjector they would prefer to
use for self-injection of their RA treatment
(Benepali, Enbrel MYCLIC, or no preference),
taking into consideration the information that
they had received from the instructional video
and device-handling leaflet, their own previous
experience of handling the Enbrel MYCLIC
autoinjector and their first experience of
handling the Benepali autoinjector. Patients
were then asked to select the top three
attributes that drove their preference for one
autoinjector over the other, based on the
attributes assessed in section 1 of the
questionnaire. The final section of the
questionnaire included questions on patient
demographics, including country of origin,
gender, and age (see supplementary material
for full details on the questionnaire).
Data Analysis
The analysis population included all patients
who completed the survey. During the
face-to-face interviews, patient responses were
recorded by the interviewer and data input from
all interviews was collected by the recruitment
agency (Schmiedl Marktforschung GmbH). All
analyses were performed by Kantar Health.
Based on the results of previous quantitative
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primary market research surveys, a minimum of
30 respondents per country is a validated and
robust sample size and an eligible base for
significant testing [19]. Statistical significance
was estimated using Student’s t test (Microsoft




A total of 220 patients from France (n = 30),
Germany (n = 65), Italy (n = 67), Spain (n = 12),
and the UK (n = 46) participated in this survey.
The lower number from Spain was due to the
lower availability of patients with the required
experience in using the Enbrel MYCLIC
autoinjector. The majority of patients were
female (72%) and aged 51–60 years (36%)
(Table 1). All patients participating in the
survey were using the Enbrel MYCLIC
autoinjector.
Importance of Attributes when Using
an Autoinjector Device for Self-injection
Patients were asked to evaluate the importance
of ten attributes, when using an autoinjector
device in general for self-injection of their RA
medication, on a seven-point scale (1 = not
important at all; 7 = extremely important).
Overall, ‘easy to operate the self-injection’ was
ranked as the most important attribute by
patients (mean score of 6.8), followed by ‘easy
to grip’ (6.5), ‘intuitive/self-explaining usage’
(6.3), ‘visual feedback after treatment has been
successfully injected’ (6.0), ‘concealing the
injection needle in the injector body’ (5.9),
and ‘audible feedback after treatment has been
successfully injected’ (5.8). The attributes of
‘button-free device’, ‘weight of the
autoinjector’, and ‘size of the autoinjector’
were considered by patients to be of less
importance, with mean scores of 5.3, 5.3, and
5.1, respectively (Fig. 1).
Patient Preferences for Autoinjector Based
on Attributes Assessed
Patients were asked for their preference of
autoinjector based on nine of the ten
attributes previously assessed (‘button-free
device’ was not included in this section).
Overall, the attribute of ‘easier to operate’ was
a strong differentiator for the Benepali
autoinjector compared to the Enbrel MYCLIC
autoinjector, with 78% of patients reporting
that the Benepali autoinjector was ‘easier to
operate’ than the Enbrel MYCLIC autoinjector
(Fig. 2). Furthermore, country-specific data
showed that patients from all five EU
countries preferred the Benepali autoinjector
Table 1 Demographic and baseline characteristics of
patients participating in the survey (n = 220)
Characteristic Description Number of patients,
n (%)





Gender Male 62 (28%)
Female 158 (72%)
Age B30 years old 4 (2%)
31–40 years old 27 (12%)
41–50 years old 66 (30%)
51–60 years old 78 (36%)
C61 years old 45 (20%)
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compared to the Enbrel MYCLIC autoinjector
based on the attribute of ‘easier to operate’
(Fig. 3).
Overall, patients preferred the Benepali
autoinjector compared to the Enbrel MYCLIC
autoinjector for attributes of ‘easier to grip’,
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‘more intuitive to use’, ‘better visual feedback’,
‘right weight’, ‘better size’, and ‘attractive
design’ (Fig. 2). The attribute of ‘conceals the
injection needle better’ was rated as being the
same for both autoinjectors by 72% of patients.
Patient Preference for Autoinjector
and Attributes that Drive Patient Choice
of Autoinjector
Patients were asked their opinion as to which
autoinjector they would prefer to use for
self-injection of their RA treatment. The
majority of patients (n = 163/220 [74%])
reported that they would prefer to use the
Benepali autoinjector, with only a small
number of patients (n = 28/220 [13%])
reporting a preference for the Enbrel MYCLIC
autoinjector. In addition, 29 patients (13%)
stated that they had no preference for either
device. A preference for the Benepali
autoinjector was also reported across all five
EU countries (Fig. 4).
Patients were also asked to select the top
three attributes that drove their preference for
one autoinjector over the other. Of the 163
patients who preferred the Benepali
autoinjector, the reasons most commonly
given were ‘easy to operate the self-injection’
(n = 117), followed by ‘button-free autoinjector’
(n = 110). Of the 29 patients who preferred the
Enbrel MYCLIC autoinjector, the most common
reasons given were ‘easy to operate’ (n = 26),
and ‘intuitive/self-explaining usage’ (n = 17)
(Fig. 5).
DISCUSSION
Results from this patient survey (n = 220)
conducted in five countries in the EU reported
that the majority of patients (74%) who were
using the Enbrel MYCLIC autoinjector preferred
the Benepali autoinjector to the Enbrel MYCLIC
autoinjector for self-injection of their RA
medication. These results were closely aligned
with those of the recently reported nurse survey
Fig. 4 Patient
opinions as to which
autoinjector they





the attribute of ‘easier
to operate the self-in-
jection’: Coun-
try-speciﬁc data
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(n = 149), which was based on the same
protocol, and reported that 86% of nurses felt
that their patients would prefer the Benepali
autoinjector [17].
Overall, attributes of ‘easy to operate the
self-injection’, ‘easy to grip’, and
‘intuitive/self-explaining usage’ were
considered by patients as being the most
important attributes when using an
autoinjector to manage their RA. This was
consistent with the results from the nurse
survey, in which these three attributes were
also considered by nurses as being the most
important attributes when selecting an
autoinjector for their patients with RA [17]. In
line with the nurse survey, patients rated the
attribute of ‘easy to operate the self-injection’ as
a strong differentiator for the Benepali
autoinjector compared to the Enbrel MYCLIC
autoinjector in this survey. However, the
attribute of ‘intuitive/self-explaining usage’,
which nurses reported as a strong
Fig. 5 Top three attributes driving patient selection
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differentiator for the Benepali autoinjector [17],
was considered by patients in this survey as
being a moderate differentiator. Finally,
attributes of ‘easy to operate the self-injection’
and ‘button-free autoinjector’ were reported as
key drivers impacting patients’ choice of
autoinjector. Once again, these results were
identical to those reported from the nurse
survey, in which these two attributes were also
reported as being key drivers impacting nurses’
choice of autoinjector [17]. Altogether, the
attributes of the Benepali autoinjector that
patients most preferred, which were in
alignment with results from the nurse survey
[17], can be described as those that make the
handling process easier for the patient,
suggesting that both patients and nurses in
Europe consider the Benepali autoinjector to be
easier to handle than the Enbrel MYCLIC
autoinjector. This is of paramount importance,
as many patients with RA suffer from
compromised dexterity, which can affect the
ability to perform the steps required [20].
Adherence to biological therapy is essential
for sustaining long-term efficacy and
optimizing therapeutic outcomes in patients
with RA. However, adherence to the therapeutic
regimen has been reported as low (varying from
30 to 80%), with the route of administration
being an important factor in treatment
adherence [21, 22]. Delivery of Benepali with
the autoinjector, which appears to be easily
performed by patients with RA, may increase
patient tolerance of self-administration,
possibly improving adherence, which in turn
could significantly improve the effectiveness of
drug therapy.
As with all market research, there are some
limitations to this survey that need to be
acknowledged. The survey results are based on
patient perception of the Benepali autoinjector
rather than actual clinical experience and do
not represent a global perspective, as all patients
came from Europe. In addition, the low patient
numbers from Spain mean that results cannot
be extrapolated to Spain. Furthermore, as
patients volunteered to participate in the
survey, an inherent self-selection bias may
have been present, along with interviewer
bias. However, to minimize selection bias,
screening criteria were developed and
rigorously adhered to, ensuring that only
patients representative of the target
population were recruited into the survey.
Similarly, to reduce interviewer bias,
comprehensive briefings were conducted with
all interviewers across the five EU countries to
ensure that all interviews were conducted in an
identical manner. Finally, results from this
survey are based on patients’ perceptions of
the Enbrel MYCLIC autoinjector following
usage of at least 1 month at the time of
recruitment compared to a demonstration of
the Benepali autoinjector only. As such, a
further survey is warranted to determine if
results of this survey are replicated after
exposure to both autoinjectors for the same
time period. Despite these limitations, the fact
that findings from this patient survey mirrored
those of the nurse survey, which was based on
the same protocol [17], and demonstrated a
large patient preference for the Benepali
autoinjector, provides further credence to
these results.
Although the biosimilars market is relatively
new in Europe, a preliminary analysis of pricing
behavior indicates that biosimilars in some
therapeutic areas are priced below reference
biologics, often with discounts of 10–35% [23].
Due to the lower cost of biosimilars versus
reference products, there has been considerable
interest in determining whether patients who
have already been treated on a reference
product treatment can be switched to its
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biosimilar without adverse consequences. To
date, a number of switching studies in patients
with RA and ankylosing spondylitis have shown
that biosimilars can be used in place of
reference products while maintaining efficacy
and safety [24–27], although, as yet, no
independent randomized controlled trials have
reported switching from original to biosimilar
drugs. The availability of Benepali, the first
etanercept biosimilar available in Europe, may
help to reduce costs, thereby relieving the
burden on healthcare budgets and improving
patient access to treatment [13]. Moreover, the
fact that patients reported a preference for the
Benepali autoinjector over the Enbrel MYCLIC
autoinjector may provide an additional
consideration point for clinicians when
considering a patient’s therapy. In addition,
lower costs may also assist in the overall earlier
introduction of biological therapy [26, 28],
thereby providing a unique opportunity to
change the course of RA, after the start of
symptoms but before the onset of radiographic
damage [29].
CONCLUSIONS
Benepali, the first etanercept biosimilar, has
now been approved in the EU for the treatment
of RA. Results from this patient survey in five EU
countries reported that, overall, patients
preferred the Benepali autoinjector compared
to the Enbrel MYCLIC autoinjector for the
majority of attributes assessed, a finding that
was in alignment with results from a recently
reported nurse survey [22]. Notably, patients
preferred the Benepali autoinjector for
attributes of ‘easy to operate the self-injection’
and ‘easy to grip’, suggesting that patients
found the Benepali autoinjector easier to
handle than the Enbrel MYCLIC autoinjector.
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